CS
IMVT icon

Credit Suisse’s Immunovant IMVT Stock Holding History

Credit Suisse’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$2.2M Buy
68,119
+12,063
+22% +$440K ﹤0.01% 1784
2023
Q4 		$2.36M Buy
56,056
+24
+0% +$883 ﹤0.01% 1785
2023
Q3 		$2.15M Sell
56,032
-6,562
-10% -$148K ﹤0.01% 1796
2023
Q2 		$1.19M Buy
62,594
+12,192
+24% +$227K ﹤0.01% 2272
2023
Q1 		$782K Buy
50,402
+1,491
+3% +$25.9K ﹤0.01% 2470
2022
Q4 		$868K Buy
48,911
+8,632
+21% +$109K ﹤0.01% 2440
2022
Q3 		$225K Buy
40,279
+3,266
+9% +$16K ﹤0.01% 3204
2022
Q2 		$145K Buy
37,013
+2,140
+6% +$9.24K ﹤0.01% 3434
2022
Q1 		$192K Buy
34,873
+11,413
+49% +$71.1K ﹤0.01% 3383
2021
Q4 		$200K Buy
23,460
+2,020
+9% +$16.7K ﹤0.01% 4276
2021
Q3 		$186K Sell
21,440
-47,139
-69% -$425K ﹤0.01% 4243
2021
Q2 		$724K Buy
68,579
+20,267
+42% +$283K ﹤0.01% 3608
2021
Q1 		$775K Sell
48,312
-17,292
-26% -$456K ﹤0.01% 3480
2020
Q4 		$3.03M Buy
65,604
+26,518
+68% +$1.23M ﹤0.01% 2511
2020
Q3 		$1.38M Buy
39,086
+25,708
+192% +$773K ﹤0.01% 2707
2020
Q2 		$325K Buy
+13,378
New +$287K ﹤0.01% 3541

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Credit Suisse's IMVT Position: Q1 2024 in Review

Credit Suisse increased its Immunovant (IMVT) stake by 22% in Q1 2024, buying an estimated $440K and bringing the position to 68,119 shares worth $2.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1784.

Credit Suisse first reported a position in IMVT in Q2 2020 and has held it in 16 quarters since. The position peaked at $3.03M in Q4 2020. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

  • Credit Suisse held 68,119 shares of Immunovant worth $2.2M as of Q1 2024.
  • Credit Suisse bought 12,063 Immunovant shares in Q1 2024, an estimated $440K.
  • Immunovant made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1784 holding.
  • Credit Suisse first reported a position in Immunovant in Q2 2020 and has held it in 16 quarters since.
  • Credit Suisse's Immunovant position peaked at $3.03M in Q4 2020.
  • 209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.